Member Info for crumbs

lol of course it is bottom of that list.... guess what..... if we win it watch it rise on that list lol...

What?... If project blueprint win expect an RG tweet storm... funny that his last tweet yesterday is a CRUK one mentioning GC... very downplayed that... I doubt the trinty part about GC was anything our BOD wrote for them... There are no bad angles to winning or even from getting to the finals of the GC none not one... why all of sudden posters are trying to create them out of thin air makes me think hmmmm....

GC is a distraction let us have 100 more lol.....Sahin and Lindy have been working on this for ages... it all fits in with scancells lab work basically CRUK would be funding moditope development how can that ever be a 'distraction' is beyond me:)
One thing a win may prompt.... is commercial deals for scancell... might give BioNtech the nudge and who knows Genetech too... as the issue of IP if moditope proves itself will be who is working with scancell not who can scancell get to work with them

Each partner own their own IPs...if it works then scancell have.no worries lol

If project blueprint does get a win on GC it means all of scancells techs would have been helped out with funds from CRUK... makes it even easier to feel good about donating to them :)

https://www.lsxleaders.com/blog/cancer-research-uk-partnering-to-accelerate-cancer-research-translation-and-commercialisation

It is the CRUK article I posted here the other day... hmm

You can see how much Merck is in love with their Keytruda from reading it too lol...

Particularly like...'But to make this work, you’re going to have to treat solid tumors. And if you’re going to do solid tumors, you have to find a tumor-specific antigen to wipe out. Guess what? People have been looking for tumor-specific antigens for the last 50 years. We don’t have any.'

Now that is why BioNtech and others may need moditope innit

Oops... the link!

https://xconomy.com/national/2019/01/16/merck-and-the-future-of-immuno-oncology-a-chat-with-roger-perlmutter/

Interesting article this...An interview with Roger Perlmutter of Merck about immunotherapy... this is what he thinks of CAR T....might be why we have not seen Merck move in on that...

'RP: I love the CAR-T data in hematological malignancies. People’s lives have been saved, so that’s great. But to make this work, you’re going to have to treat solid tumors. And if you’re going to do solid tumors, you have to find a tumor-specific antigen to wipe out. Guess what? People have been looking for tumor-specific antigens for the last 50 years. We don’t have any.

The second problem is the industrialization of the process. Right now, with autologous transplant—we remove a blood sample from you, engineer it to kill your tumor cells, and in 14 days return the sample to you—the chain-of-custody issue becomes a big deal. Anybody who’s practiced medicine knows how often blood transfusions are mismatched. I hate to bet against American engineers, or any engineers for that matter, but the full-scale throughput for CAR-T is very small.

David Chang, who developed Yescarta [one of two FDA-approved CAR-T therapies] at Kite Pharma, and who used to work for me at Amgen, spent a lot of time talking to me about this. When Kite was acquired by Gilead [Sciences], the maximum throughput in their new facility was six patients a week. I’m not interested in treating six patients a week. I need to treat 100,000 patients. How am I going to do that?

The future for those kinds of therapies is tumor-specific antigens and allogeneic [‘off the shelf’] treatments, so you’ve got something in a bottle.'

Have also funded Lindys Glyco MABs to the tune of £225k...

'Prof Lindy Durrant, Dr Ian Spendlove
Cancer Research UK (£225,000)
Platform technology for producing anti-glycolipid monoclonal antibodies: lead optimisation of anti-Lewis g monoclonal antibodies to fucosyl-GM1 and Gb3. '

Nice to have that work with us now

Why are we at 8p?... easy - the last raising was at 10p to fund the longest ever awaited SCIB1 combo US trial .... trial got delayed!... and with no more news of certain progress that is why we have ended up at 8p... how we got to 10p is another story :))) though that can all be traced back to the AGM of doom and SCIB1 deal falling through... so a mixture of events or non-events and sentiment.... (will throw in MM factor for fun :p)

PBP basically is made up of people connected to Lindy... we can say she is very well connected!

Opportunity...
Project Description
Proteins perform a wide range of biological functions and are often adapted after they are made by post-translational modifications. Some of these modifications are transient, such as phosphorylation, to control cellular signalling. Other modifications are longer-lived and can be a hallmark of disease, such as citrullination (the deamination of arginine), which occurs during ageing, inflammatory disease and cancer.
In this project between Durham and Liverpool Universities, we will employ new, cutting-edge mass spectrometry techniques and proteomics to probe how cells process and present post-translationally modified peptides for recognition by the immune system.

Working with an industrial CASE partner, Scancell, we will use cell and tissue models to define how the immuno-proteome and peptidome can be exploited for the design of novel vaccines and therapeutics.

For further information see the website: https://www.dur.ac.uk/biosciences/

I'd personally say we would be higher than a Kite :)....

Yes of course winning does not prove moditope... however winning would get us those potential 4 extra trial targets.. which we would not have so soon otherwise... imagine... scancell, in theory, could be in the clinic in up to 20 cancer targets within the next couple of years... now that would be some pipeline!

Basically, there is no bad angle for scancell if project blueprint wins a GC prize and plenty of potentially very good angles...

No scancells part will be just moditope which scancell own there will be no IP dilution at all and project blueprint will use techs from BioNtech and Genentech ,ISA and Tron too all to create personalised answers to individual patients cancers... with our Lindy overseeing it all...

modi 3 as part of project blueprint would get all pre clinical development expenses paid and most enticing of all a proof of concept clinical trial in up to 4 very hard to treat cancer targets.... all paid for with no dilution to IP... and all working alongside some of the biggest brightest names in immuno onco... not to mention we get to work with BioNtech who fancy themselves as Europes number one in the field and Genentech/Roche who fancy themselves as global number one ... and have the funds to get there... but maybe not all the techs :)))

We have seen it many times before and is indeed usually an ii.... they do not run on timelines of news expect etc... though if it is an ii... doubt they are selling at a profit all 10p raising supports at a loss now... not very good pr for any future needed market raises! So let us hope we will not need one or at least not one with such a low sp...